


## DIM-C-pPhOCH<sub>3</sub>

<b>Cat. No.:</b>	HY-111492		
<b>CAS No.:</b>	33985-68-1		
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>20</sub> N <sub>2</sub> O		
<b>Molecular Weight:</b>	352.43		
<b>Target:</b>	Nuclear Hormone Receptor 4A/NR4A		
<b>Pathway:</b>	Vitamin D Related/Nuclear Receptor		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 33.3 mg/mL (94.49 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
	1 mM		2.8374 mL	14.1872 mL	28.3744 mL
	5 mM		0.5675 mL	2.8374 mL	5.6749 mL
	10 mM		0.2837 mL	1.4187 mL	2.8374 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

DIM-C-pPhOCH<sub>3</sub> is a Nur77 agonist. Nerve growth factor-induced Ba (NGFI-Ba, Nur77) is an orphan nuclear receptor.

#### IC<sub>50</sub> & Target

Nur77/NR4A1

#### In Vitro

DIM-C-pPhOCH<sub>3</sub> decreases survival and induces apoptosis in RKO colon cancer cells, and this is accompanied by induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein. DIM-C-pPhOCH<sub>3</sub> also induces Nur77-independent apoptosis. DIM-C-pPhOCH<sub>3</sub> (10 μM) inhibits cell growth after treatment for 24, 48, or 72 h, and the maximum inhibitory response is observed after 72 h, where there is considerable cell detachment and dead cells. The growth-inhibitory effects observed for DIM-C-pPhOCH<sub>3</sub> after 72 h are also accompanied by several markers of apoptosis, including

PARP cleavage and cleavage of caspase-3, caspase-9, and caspase-8. PARP cleavage is also observed after treatment of RKO cells for 48 h with DIM-C-pPhOCH<sub>3</sub><sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

DIM-C-pPhOCH<sub>3</sub> (25 mg/kg/d) also inhibits tumor growth in athymic nude mice bearing RKO cell xenografts. The effects of DIM-C-pPhOCH<sub>3</sub> (25 mg/kg/d) on colon tumor growth are also investigated in athymic nude mice bearing RKO cell xenografts. Treatment with the DIM-C-pPhOCH<sub>3</sub> significantly decreases tumor volumes and final tumor weights compared with corn oil controls<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Cell Assay <sup>[1]</sup>

RKO cells are treated with DMSO or 12.5 μM DIM-C-pPhOCH<sub>3</sub> for 2 and 6 h. RNA is isolated for the reverse transcription-PCR (RT-PCR) experiment and analyzed for gene expression, and three replicates are determined for each time point and the DMSO control. The microarray data are analyzed<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Animal Administration <sup>[1]</sup>

Mice<sup>[1]</sup>

Male athymic nude mice (*Foxn1<sup>nu</sup>*, ages 7-8 weeks) are used. The mice are housed and maintained in laminar flow cabinets under specific pathogen-free conditions. A xenograft is established by s.c. injection of in vitro cultured RKO cells (5×10<sup>6</sup> per 150 μL) into the flanks of individual mice. Tumors are allowed to grow for 4 days until tumors are palpable. Mice are then randomized into two groups of six mice per group and dosed by oral gavage with either corn oil or 25 mg/kg/d DIM-C-pPhOCH<sub>3</sub> for 21 days. The mice are weighed, and tumor size is measured<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Cho SD, et al. Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and nuclear receptor-independent pathways. *Cancer Res.* 2007 Jan 15;67(2):674-83.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA